Research Analysts Offer Predictions for CNTX FY2025 Earnings

Context Therapeutics Inc. (NASDAQ:CNTX) – Analysts at Lifesci Capital issued their FY2025 earnings per share (EPS) estimates for shares of Context Therapeutics in a note issued to investors on Monday, February 23rd. Lifesci Capital analyst C. Zhu anticipates that the company will earn ($0.36) per share for the year. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Context Therapeutics’ Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.55) EPS.

CNTX has been the topic of a number of other reports. JonesTrading assumed coverage on shares of Context Therapeutics in a research note on Monday, December 22nd. They set a “buy” rating and a $7.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen upgraded Context Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 16th. D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Thursday, November 6th. Finally, HC Wainwright upped their price target on Context Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $6.00.

Context Therapeutics Trading Up 8.8%

Shares of CNTX stock opened at $2.48 on Wednesday. Context Therapeutics has a twelve month low of $0.49 and a twelve month high of $2.85. The company’s 50-day moving average price is $1.83 and its 200-day moving average price is $1.32. The stock has a market cap of $227.86 million, a price-to-earnings ratio of -10.33 and a beta of 1.94.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CNTX. State Street Corp lifted its position in Context Therapeutics by 8.5% during the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after buying an additional 13,000 shares in the last quarter. Blue Owl Capital Holdings LP increased its position in shares of Context Therapeutics by 0.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after acquiring an additional 25,000 shares during the last quarter. Virtu Financial LLC bought a new stake in Context Therapeutics during the fourth quarter worth about $43,000. Clear Harbor Asset Management LLC boosted its position in Context Therapeutics by 60.5% during the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after purchasing an additional 35,000 shares during the last quarter. Finally, Quadrature Capital Ltd bought a new position in Context Therapeutics in the fourth quarter valued at approximately $68,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.